EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis
- Rheumatoid Arthritis
- Agios Syllas, Kavala
- Nea Smyrni
The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.
The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.
The purpose of this study is to evaluate the percentage of participants treated with subcutaneous (SC) Tocilizumab who are still on treatment after 52 weeks and the factors that play a major role in continuation of treatment.
Multicenter, Post-Marketing, Non-Interventional, Observational Study to Evaluate Persistence to Tocilizumab SC as Monotherapy or in Combination With cDMARD Treatment in RA Patients in Greece: the EMBRACE-SC Study.
- Aged >/= 18 years of age with rheumatoid arthritis (RA) for whom the treating physician
has made the decision to start subcutaneous (SC) Tocilizumab (TCZ) treatment according to
approved label within 4 weeks prior to enrolment.
- Participants who have been receiving Tocilizumab (TCZ) for more than 4 weeks prior to enrolment.
- Participants who have received TCZ in past treatments.
- Participants who have received treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational agent, whichever is longer) of starting treatment TCZ SC.
- Participants with a history of autoimmune disease or of any joint inflammatory disease other than rheumatoid arthritis (RA).
For the latest version of this information please go to www.forpatients.roche.com